BackgroundADHD is a common neurodevelopmental disorder. Stimulants are the gold standard treatment resulting in measurable improvements in associated functional impairment. However, people with a history of comorbid anorexia nervosa (AN), an illness characterised by restricted intake and malnutrition, find it challenging to access stimulant treatment. In our clinical experience, amidst a scarce safety-profile for this population, stimulants are ceased or withheld due to concerns about appetite…
